Cargando…
SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER
BACKGROUND: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and highly aggressive tumor that occurs most commonly in infants and young children. The prognosis for patients with AT/RT is generally poor, with a five-year survival rate of less than 30%. METHODS: We retrospectively analyzed the clini...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402340/ http://dx.doi.org/10.1093/noajnl/vdad070.078 |
_version_ | 1785084853778120704 |
---|---|
author | Li, Juan Ai, Ruyu Lai, Mingyao Hu, Qingjun Cai, Linbo |
author_facet | Li, Juan Ai, Ruyu Lai, Mingyao Hu, Qingjun Cai, Linbo |
author_sort | Li, Juan |
collection | PubMed |
description | BACKGROUND: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and highly aggressive tumor that occurs most commonly in infants and young children. The prognosis for patients with AT/RT is generally poor, with a five-year survival rate of less than 30%. METHODS: We retrospectively analyzed the clinical data of patients with AT/RT in the past 10 years at the Guangdong Sanjiu Brain Hospital RESULTS: A total of 18 cases (male/female = 9:9; median age at diagnosis, 3.5 years (range 1-58 years old)) were diagnosed with AT/RT between 2017 and 2023. AT/RT had higher prevalence in children < 36 months (55.6%), and at infratentorial (66.7%). The median follow-up time was 15.5 months, with a range of 2-62 months. Survival analyses demonstrated that patients > 3 years of age (n = 9 (50%)) had median survival time 28months and patients ≤ 3 years of age (n = 9 (50%)) had median- survival time 15 months (p =0.034) The average survival time for disseminated tumor was 15 months, and for patients with localizedtumors was 44 months. (P=0.012) CONCLUSION: Older age, localized tumor improves the survival of patients with AT/RT. |
format | Online Article Text |
id | pubmed-10402340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-104023402023-08-05 SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER Li, Juan Ai, Ruyu Lai, Mingyao Hu, Qingjun Cai, Linbo Neurooncol Adv Final Category: Screening/Diagnostics/Prognostics BACKGROUND: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and highly aggressive tumor that occurs most commonly in infants and young children. The prognosis for patients with AT/RT is generally poor, with a five-year survival rate of less than 30%. METHODS: We retrospectively analyzed the clinical data of patients with AT/RT in the past 10 years at the Guangdong Sanjiu Brain Hospital RESULTS: A total of 18 cases (male/female = 9:9; median age at diagnosis, 3.5 years (range 1-58 years old)) were diagnosed with AT/RT between 2017 and 2023. AT/RT had higher prevalence in children < 36 months (55.6%), and at infratentorial (66.7%). The median follow-up time was 15.5 months, with a range of 2-62 months. Survival analyses demonstrated that patients > 3 years of age (n = 9 (50%)) had median survival time 28months and patients ≤ 3 years of age (n = 9 (50%)) had median- survival time 15 months (p =0.034) The average survival time for disseminated tumor was 15 months, and for patients with localizedtumors was 44 months. (P=0.012) CONCLUSION: Older age, localized tumor improves the survival of patients with AT/RT. Oxford University Press 2023-08-04 /pmc/articles/PMC10402340/ http://dx.doi.org/10.1093/noajnl/vdad070.078 Text en © The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Final Category: Screening/Diagnostics/Prognostics Li, Juan Ai, Ruyu Lai, Mingyao Hu, Qingjun Cai, Linbo SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER |
title | SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER |
title_full | SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER |
title_fullStr | SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER |
title_full_unstemmed | SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER |
title_short | SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER |
title_sort | sdps-22 the clinical outcomes of atypical teratoid/rhabdoid tumor from one single clinical center |
topic | Final Category: Screening/Diagnostics/Prognostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402340/ http://dx.doi.org/10.1093/noajnl/vdad070.078 |
work_keys_str_mv | AT lijuan sdps22theclinicaloutcomesofatypicalteratoidrhabdoidtumorfromonesingleclinicalcenter AT airuyu sdps22theclinicaloutcomesofatypicalteratoidrhabdoidtumorfromonesingleclinicalcenter AT laimingyao sdps22theclinicaloutcomesofatypicalteratoidrhabdoidtumorfromonesingleclinicalcenter AT huqingjun sdps22theclinicaloutcomesofatypicalteratoidrhabdoidtumorfromonesingleclinicalcenter AT cailinbo sdps22theclinicaloutcomesofatypicalteratoidrhabdoidtumorfromonesingleclinicalcenter |